Logo

Calibrant, Yale to Collaborate on Ovarian, Breast Cancer Drug ID Study

Feb 07, 2008
NEW YORK (GenomeWeb News) – Calibrant Biosystems today said that it will collaborate with researchers at the Yale University School of Medicine to identify ovarian and breast cancer drug targets from clinical tissue specimens using Calibrant’s Gemini proteomics platform.
 
Gaithersburg, Md.-based Calibrant said that it would identify proteins and protein networks involved in ovarian and breast cancer and select therapeutic targets found to be central to disease progression. The firm will collaborate with Fattaneh Tavasolli, a professor of pathology and director of the Women’s Health Program/Gynecology and Breast Pathology at Yale.
 
Terms of the collaboration were not disclosed.

Breaking News
The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.